Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
KMDA
$7.37
Kamada
($.03)
(.41%)
KMDA
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus: $0.11
Revenue: $37.66 Mil
Wednesday
Feb 12
7:00 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Wednesday, November 13, 2019
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019
What do you expect when KMDA reports earnings?
Beat
Meet
Miss
Where is KMDA's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
Peers
BioMarin Pharmaceutical
Regeneron Pharmaceuticals
InterCept
Vertex Pharmaceuticals
Johnson & Johnson
Zoetis
Bristol-Myers Squibb
Endo International plc
Mylan
Ultragenyx Pharmaceutical
Expectations
›
Kamada
